Therapeutic potential of CDK5 inhibitors to promote corneal epithelial wound healing

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 7, 2005, Pages 875-887

  Zelenka, Peggy S ^a   Smith, Janine ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Cornea; Cyclin dependent kinase; Diabetic keratopathy; Epithelium; Infectious keratitis; Neurotorophic keratopathy; Wound healing

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ALOISINE; ANTIGLAUCOMA AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 5 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DICLOFENAC; FLAVONE DERIVATIVE; INDAZOLE DERIVATIVE; INDIRUBIN; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; OLOMOUCINE; PAULLONE DERIVATIVE; PHENOL DERIVATIVE; PHTHALAZINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; ROSCOVITINE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

CORNEA DISEASE; CORNEA EPITHELIUM; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IATROGENIC DISEASE; KERATITIS; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; NONHUMAN; PATENT; REVIEW; TREATMENT INDICATION; WOUND HEALING;

EID: 22744441684     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.7.875     Document Type: Review

References (68)

1. DHAVAN R, TSAI LH: A decade of CDK5. Nat. Rev. Mol. Cell. Biol. (2001) 2:749-759.
2. LAZARO JB, VANDROMME M, POUL MA, FERNANDEZ A, LAMB M: CDK5 is a positive regulator necessary for myogenesis of C2 cells. Mol. Biol. Cell (1995) 6(Suppl. Nov.):242a.
3. GAO CY, ZAKERI Z, ZHU Y, HE HY, ZELENKA PS: Expression of CDK-5, p35, and CDK5-associated kinase activity in the developing rat lens. Develop. Genetics (1997) 20:267-275.
4. CHEN F, STUDZINSKI GP: Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. Blood (2001) 97:3763-3767.
5. TARRICONE C, DHAVAN R, PENG J et al.: Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell Neurosci. (2001) 8:657-669.
6. ZUKERBERG LR, PATRICK GN, NIKOLIC M et al.: Cables links CDK5 and c-Abl and facilitates CDK5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron (2000) 26:633-646.
7. SASAKI Y, CHENG C, UCHIDA Y et al.: Fyn and CDK5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex. Neuron (2002) 35:907-920.
8. MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131-134.
9. OHSHIMA T, GILMORE EC, LONGENECKER G et al.: Migration defects of CDK5(-/-) neurons in the developing cerebellum is cell autonomous. J. Neurosci. (1999) 19:6017-6026.
10. TAN TC, VALOVA VA, MALLADI CS et al.: CDK5 is essential for synaptic vesicle endocytosis. Nat. Cell Biol. (2003) 5(8):701-10.
11. MOY LY, TSAI LH: Cyclin-dependent kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability. J. Biol. Chem. (2004) 279:54487-5493.
12. KANSY JW, DAUBNER SC, NISHI A et al.: Identification of tyrosine hydroxylase as a physiological substrate for CDK5. J. Neurochem. (2004) 91:374-84.
13. LI BS, ZHANG L, TAKAHASHI S et al.: Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J. (2002) 21:324-333.
14. LI BS, MA W, JAFFE H et al.: Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem. (2003) 278(37):35702-35709.
15. CHERGUI K, SVENNINGSSON P, GREENGARD P: Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc. Natl. Acad. Sci. USA (2004) 101:2191-2196.
16. TAKAHASHI S, OHSHIMA T, CHO A et al.: Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc. Natl. Acad. Sci. USA (2005) 102:1737-1742.
17. PATRICK GN, ZUKERBERG L, NIKOLIC M et al.: Conversion of p35 to p25 deregulates CDK5 activity and promotes neurodegeneration. Nature (1999) 402:615-622.
18. LEE M-S, KWON YT, LI M et al.: Neurotoxicity induces cleavage of p35 to p25 by calpain Nature (2000) 405:360-364.
19. PATZKE H, TSAI LH: Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. (2002) 277:8054-8060.
20. KESAVAPANY S, LAU KF, MCLOUGHLIN DM et al.: p35/CDK5 binds and phosphorylates β-catenin and regulates β-catenin /presenilin-1 interaction. Eur. J. Neurosci. (2001) 13:241-247.
21. LEDEE DR, GAO CY, SETH R et al.: A specific interaction between muskelin and the cyclin dependent kinase 5 activator p39 promotes peripheral localization of muskelin. J. Biol. Chem. (2005) Mar 28:(Epub ahead of print).
22. NEGASH S, WANG HS, GAO C, LEDEE D, ZELENKA P: CDK5 regulates cell-matrix and cell-cell adhesion in lens epithelial cells. J. Cell Sci. (2002) 115:2109-2117.
23. PHILPOTT A, PORRO EB, KIRSCHNER MW, TSAI L-H: The role of cyclin-dependent kinase 5 and a novel regulatory subunit in regulating muscle differentiation and patterning. Genes Dev. (1997) 11:1409-1421.
24. LAZARO J-B, KITZMANN M, POUL M-A et al.: Cyclin-dependent kinase 5, CDK5, is a positive regulator of myogenesis in mouse C2 cells. J. Cell Sci. (1997) 110:1251-1260.
25. FU AK, FU WY, NG AK et al.: Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. Proc. Natl. Acad. Sci. USA (2004) 101:6728-6733.
26. FU WY, FU AK, LOK KC, IP FC, IP NY: Induction of CDK5 activity in rat skeletal muscle after nerve injury. Neuroreport (2002) 13:243-247.
27. FU AK, FU WY, CHEUNG J et al.: CDK5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat. Neurosci. (2001) 4:374-381.
28. LILJA L, YANG SN, WEBB DL et al.: Cyclin-dependent kinase 5 promotes insulin exocytosis. J. Biol. Chem. (2001) 276:34199-34205.
29. CHEN F, RAO J, STUDZINSKI GP: Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells. J. Leukoc. Biol. (2000) 67:559-566.
30. ALEXANDER K, YANG HS, HINDS PW: Cellular senescence requires CDK5 repression of Rac1 activity. Mol. Cell Biol. (2004) 24:2808-2819.
31. GAO C, NEGASH S, GUO HT et al.: CDK5 Regulates cell adhesion and migration in corneal epithelial cells. Mol. Cancer Res. (2002) 1:12-24.
32. GAO CY, STEPP MA, FARISS R, ZELENKA PS: CDK5 regulates activation and localization of Src during corneal epithelial wound closure. J. Cell Sci. (2004) 117:4089-4098.
33. SUZUKI K, SAITO J, YANAI R et al.: Cell-matrix and cell-cell interactions during corneal epithelial wound healing. Prog. Retin. Eye Res. (2003) 22:113-133.
34. ZHAO M, SONG B, PU J, FORRESTER JV, MCCAIG CD: Direct visualization of a stratified epithelium reveals that wounds heal by unified sliding of cell sheets. FASEB J. (2003) 17:397-406.
35. HARDARSON T, HANSON C, CLAESSON M, STENEVI U: Time-lapse recordings of human corneal epithelial healing. Acta Ophthalmol. Scand. (2004) 82:184-188.
36. DANJO Y, GIPSON IK: Actin 'purse string' filaments are anchored by E-cadherin-mediated adherens junctions at the leading edge of the epithelial wound, providing coordinated cell movement. J. Cell Sci. (1998) 111:3323-3332.
37. ETIENNE-MANNEVILLE S, HALL A: Rho GTPases in cell biology. Nature (2002) 420:629-635.
38. HOLLY SP, LARSON MK, PARISE LV: Multiple roles of integrins in cell motility. Exp. Cell Res. (2000) 261:69-74.
39. HAZLETT L: Corneal and ocular surface histochemistry. Prog. Histochem. Cytochem. (1993) 25:1-60.
40. IMANISHI J, KAMIYAMA K, IGUCHI I et al.: Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog. Retin. Eye Res. (2000) 19:113-129.
41. YAMADA N, YANAI R, INUI M, NISHIDA T: Sensitizing effect of substance P on corneal epithelial migration induced by IGF-1, fibronectin, or interleukin-6. Invest. Ophthalmol. Vis. Sci. (2005) 46:833-839.
42. FISCHER P, GIANELLA-BORRADORI A: CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs. (2003) 12:955-970.
43. EDO M, ROLDAN M, ANDRES V: cyclin-dependent protein kinases as therapeutic targets in cardiovascular disease. Expert Opin. Ther. Patents (2003) 13:579-588.
44. WAGMAN AS, JOHNSON KW, BUSSIERE DE: Discovery and development of GSK3 inhibitors for the treatment of Type 2 diabetes. Curr. Pharm. Des. (2004) 10:1105-1137.
45. MAPELLI M, MASSIMILIANO L, CROVACE C et al.: Mechanism of CDK5/p25 Binding by CDK Inhibitors. J. Med. Chem. (2005) 48:671-679.
46. ZHENG YL, KESAVAPANY S, GRAVELL M et al.: A CDK5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. (2005) 24:209-20.
47. MATSUDA T, CEPKO CL: Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl. Acad. Sci. USA (2004) 101:16-22.
48. WADIA JS, DOWDY SF: Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. (2005) 57:579-596.
49. PASTOR JC, CALONGE M: Epidermal growth factor and corneal wound healing. A multicenter study. Cornea (1992) 11:311-314.
50. GORDON JF, JOHNSON P, MUSCH DC: Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group. Am. J. Ophthalmol. (1995) 119:281-287.
51. TSUBOTA K: Ocular surface management in corneal transplantation, a review. Jpn. J. Ophthalmol. (1999) 43:502-508.
52. VAJPAYEE RB, MUKERJI N, TANDON R et al.: Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br. J. Ophthalmol. (2003) 87:1312-1316.
53. CHEN HJ, PIRES RT, TSENG SC: Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br. J. Ophthalmol. (2000) 84:826-833.
54. PUSHKER N, DADA T, VAJPAYEE RB et al.: Neurotrophic keratopathy. CLAO J. (2001) 27:100-107.
55. MAH-SADORRA JH, YAVUZ SG, NAJJAR DM et al.: Trends in contact lens-related corneal ulcers. Cornea (2005) 24:51-58.
56. MCCULLEY J, ALIZADEH H: The diagnosis and management of acanthamodeba keratitits. CLAO J. (2000) 26:47-51.
57. SUDESH S, LAIBSON PR: The impact of the herpetic eye disease studies on the management of herpes simplex vius ocular infections. Curr. Opin. Ophthalmol. (1999) 10:230-233.
58. REIDY JJ, PAULUS MP, GONA S: Recurrent erosions of the cornea: epidemiology and treatment. Cornea (2000) 19:767-771.
59. BURNS R: Meesman's corneal dystrophy. Trans. Am. Ophthalmol. Soc. (1968) 66:530-635.
60. HEYWORTH P, MORLET N, RAYNER S, HYKIN P, DART J: Natural history of recurrent erosion syndrome - a 4 year review of 117 patients. Br. J. Ophthalmol. (1998) 82:26-28.
61. ALPER MG: The anesthetic eye: an investigation of changes in the anterior ocular segment of the monkey caused by interrupting the trigeminal nerve at various levels along its course. Trans. Am. Ophthalmol. Soc. (1975) 73:313-365.
62. REID TW, MURPHY CJ, IWAHASHI CK, FOSTER BA, MANNIS MJ: Stimulation of epithelial cell growth by the neuropeptide substance P. J. Cell Biochem. (1993) 52:476-485.
63. DAVIS EA, DOHLMAN CH: Neurotrophic keratitis. Int. Ophthalmol. Clin. (2001) 41:1-11.
64. AZAR DT, SPURR-MICHAUD SJ, TISDALE AS, GIPSON IK: Decreased penetration of anchoring fibrils into the diabetic stroma. A morphometric analysis. Arch. Ophthalmol. (1989) 107:1520-1523.
65. SAITO J, ENOKI M, HARA M et al.: Correlation of corneal sensation, but not of basal or reflex tear secretion, with the stage of diabetic retinopathy. Cornea (2003) 22:15-18.
66. ANG L, TAN D: Ocular surface stem cells and disease: current concepts and clinical applications. Ann. Acad. Med. Singapore (2004) 33:576-580.
67. FURRER P, MAYER JM, PLAZONNET B, GURNY R: Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS Pharm. Sci. (2002) 4
68. SCHANG L: Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. (2002) 50:779-792.